Abbisko Therapeutics enters potential $1.9 billion R&D deal with Eli Lilly
24/06/2026 02:29
Abbisko Therapeutics enters potential $1.9 billion R&D deal with Eli Lilly June 24 (Reuters) - Abbisko Cayman 2256.HK said on Wednesday that its Shanghai-based unit Abbisko Therapeutics has entered into a strategic research collaboration and license agreement with Eli Lilly LLY.N.
The agreement will allow both firms to collaborate on the discovery and development of medicines across multiple targets, with Abbisko Therapeutics eligible for development, regulatory and commercial milestone payments of up to $1.9 billion.
(Reporting by Nichiket Sunil in Bengaluru; Editing by Subhranshu Sahu)
Recent news on Abbisko Cayman
See all newsHK-listed Abbisko climbs most in 12 weeks on Eli Lilly tie-up
Abbisko Therapeutics enters potential $1.9 billion R&D deal with Eli Lilly (updated)
Brief: Abbisko Therapeutics Deepens R+D- Collaboration With Lilly
Abbisko Therapeutics enters potential $1.9 billion R&D deal with Eli Lilly
Brief: Abbisko Therapeutics Enters Strategic Research Collaboration And License Agreement With Eli Lilly